Study Conducting By ICMR To Scrutinize The Virtue Of Covishield And Covaxin In Preventing Covid-19

Since the innovation of AstraZeneca’s Covishield and Bharat Biotech’s Covaxin in the country, the Indian Council of Medical Research (ICMR) will appraise a  study  from next week to scrutinize the potency of these vaccines in preclude the concatenation of  Covid into a critical form.

As reported by senior scientist Dr Tarun Bhatnagar  at ICMR’s National Institute of Epidemiology (NIE) in Chennai revealed that, approaching 4,000 folks  the people exceeds  the age of 45 years who have taken each of  two doses either of  two vaccines will be criticized.

“As a part of the study we will take people who are COVID-19 positive and hospitalised and compare their vaccination status with those who have tested Covid negative,” Bhatnagar told PTI. The aim is to assess how effective vaccination is in preventing progression of the disease into a severe form,” he said.

Up to the present time around 20 crore  amassed vaccine doses has disbursed  in the country  so far.

The Central Government is impelling people to get vaccinated by perpetuating that the vaccine will not fortify one from dwindle the corona virus infection but by inoculating the two doses of the vaccine it will prohibits the concatenation to a extreme stage and will bring down the fatality rate.

The central authorities has been pressurizing about the necessity of wearing a face mask and adhesion to covid protocols.

At present India is using 3 vaccines against this pandemic, which includes Covishield, Covaxin , and Sputnik. Among this covishield is  manufactured by the Pune-based Serum Institute and Covaxin of Bharat Biotech in Hyderabad. Finally the Russian Sputnik V needs the approval from Drug Controller General of India (DCGI) for Emergency Use Authorization and is hardly used in private hospitals so far.

This first of its kind study is expected to be undertaken from next week, said Dr Tarun Bhatnagar, senior ICMR scientist.

COVID-19 Vaccine Registration to Go Live in India for People Aged Above 18 Years From Today

COVID-19 vaccine registration in India for people aged between 18 and 44 years will go live from 4pm Wednesday, April 28.

This will be the third step of India’s vaccination campaign, which will broaden the current vaccination requirements to include people aged 45 and up. COVID-19 vaccination registration is required, and qualified individuals must have a valid Indian identification evidence, such as an Aadhaar card or a PAN card. India recently registered over 350,000 cases in a single day, the world’s highest total.

The government has made it mandatory for people aged 18 to 44 to register on the CoWIN portal and schedule a coronavirus vaccination appointment, stating that walk-ins would not be permitted at first to prevent “chaos” at immunisation centers until the inoculation campaign ramps up significantly.

Covaxin, produced by Hyderabad-based Bharat Biotech, and Covishield, developed by Oxford-AstraZeneca and manufactured by the Serum Institute of India, are the two COVID-19 vaccines currently being used in the vaccination campaign (SII).

Covishield, manufactured by the Serum Institute of India, will cost states Rs 400 per dose and private hospitals Rs 600 per dose, while Bharat Biotech’s Covaxi will cost states Rs 600 per dose and private hospitals Rs 1,200 per dose.

But don’t get your hopes up too high; while India has vaccinated a large number of people, we still have an absurdly large population, and the new push would simply increase the number of people who will be vaccinated.